Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Net Income

Bottom-line profit after all expenses, interest, and taxes.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income remains negative

Q4 FY2025 net income was -CN¥639.96M, compared with -CN¥568.43M a year earlier.

Context

  • Net income amounted to 216.5% of revenue in FY2025, up 175.1 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -CN¥302.5M (+75.0%) for the fiscal year ending Dec 2026, a step up from the -198.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥639.96M— QoQ
Last fiscal yearDec 2025
-CN¥1.21B-198.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.6%——
1 year-198.2%+75.0%+273.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CNY · from the income statement

Latest · FY2025
(1.21B) CNY
Year-over-year change
-198.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -198.2% is the lowest of 10, against a peer median of +11.4%.
  • Net income amounts to 216.5% of revenue for AAPG, versus a peer median of 88.2%.
AAPG Competitors
Net Income for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M USD+220.5%—42.0%
ANLAdlai Nortye Ltd.LTM Jun 2024-$54.07M USD——833.1%
IMRXImmuneering CorporationLTM Mar 2026-$54.44M USD+11.9%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$103.8M USD-0.5%—297.8%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$140.06M USD+54.3%—62.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M USD-14.0%——
NUVBNuvation Bio Inc.LTM Jun 2026-$149.83M USD+26.2%—88.2%
ZLABZai Lab LimitedLTM Jun 2026-$188.21M USD+11.4%—41.9%
VSTMVerastem, Inc.LTM Mar 2026-$193.96M USD-30.3%—391.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026-$208M USD-106.9%——
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.21B CNY-198.2%—216.5%
Peer median (excluding AAPG) —+11.4%—88.2%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.